

Statement of unaudited standalone financial results for the quarter ended 30 June 2017

		(₹ in Million except per share data)	
Particulars		Quarter ended	
		30th June 2017 Unaudited	30th June 2016 Unaudited (refer note ii)
1	Revenue from operations	483.03	393.51
2	Other Income	1.80	15.37
3	Total Income (1+2)	484.83	408.88
4	Expenses		
	(a) Cost of materials consumed	205.03	127.37
	(b) Purchases of stock-in-trade	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(27.89)	37.23
	(d) Excise duty	32.45	21.37
	(e) Employee benefits expense	87.11	67.89
	(f) Finance costs	7.41	11.68
	(g) Depreciation and amortisation expense	18.92	23.78
	(h) Other expenses	90.58	64.55
	Total Expenses	413.61	353.87
5	Profit before Exceptional item and tax (3-4)	71.22	55.01
6	Exceptional item	-	-
7	Profit before tax (5-6)	71.22	55.01
8	Tax expense		
	Current tax	19.69	18.34
	Deferred tax charge	0.73	0.77
	Total tax expense	20.42	19.11
9	Profit for the period (7-8)	50.80	35.90
10	Other comprehensive income		
	A (i) Items that will not be reclassified to profit or loss	(4.86)	(1.74)
	(ii) Income tax related to items that will not be reclassified to profit or loss	1.68	0.60
	B (i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax related to items that will be reclassified to profit or loss	-	-
	Total Other comprehensive income	(3.18)	(1.14)
11	Total comprehensive income (9+10)	47.62	34.76
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.26	217.66
13	Earnings Per Share of ₹ 2 each (not annualized)		
	(a) ₹ (Basic)	0.46	0.33
	(b) ₹ (Diluted)	0.45	0.33

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above unaudited standalone financial results for the quarter ended 30 June 2017 of Advanced Enzyme Technologies Limited (the "Company") were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 11 September 2017. The statutory auditors of the Company have carried out a limited review of the above unaudited standalone financial results pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Limited Review report does not have any qualifications. The Limited Review report will be filed with stock exchanges and will be available on the Company's website.

(ii) On April 1 2017, the Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 1 April 2016. Accordingly, the financial results for the quarter ended 30 June 2017 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and results for the comparative quarter ended 30 June 2016 have been restated in accordance with Ind AS. The financial results and the reconciliation of net profit for the quarter ended 30 June 2016 have not been audited or reviewed by the auditors and are compiled by the management by exercising necessary due diligence to ensure that these give a true and fair view of the Company's affairs.

(iii) During the quarter ended 30 September 2016, the Company completed the Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs. 10 each at an issue price of Rs. 896 per Equity share (Rs. 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) via id ADVENZYMES and on BSE Limited (BSE) via Id 540025 on 1 August 2016.

(iv) The proceeds from the IPO of Rs. 499.99 million (including issue related expenses, inclusive of service tax amounting to Rs. 29.32 million).

Details of utilization of IPO proceeds are as follows:

(₹ in million)

Particulars	As per prospectus	utilized upto 31 March 2017	unutilized amount as at 31 March 2017
Investment in Advanced Enzymes USA, Inc., the wholly owned subsidiary for repayment/pre-payment of certain loans availed by Advanced Enzymes USA, Inc.	400.00	400.00	-
General corporate purposes	71.98	70.67	1.31
Share issue expenses	28.01	29.32	(1.31)
Total	499.99	499.99	-

(v) Reconciliation of net profit as reported under Indian Generally Accepted Accounting Principles (previous GAAP) and as per Ind AS is given as follows:

(₹ in Million)

Particulars	Quarter ended
	30.06.2016 unaudited
Net profit after tax for the period under previous GAAP	37.08
Add/ (less): adjustments for GAAP differences	
Amortisation of leasehold land	(0.02)
Provision for sales return	(0.70)
Net Actuarial loss on employees defined benefit plan reclassified to other comprehensive income	1.74
Provision for doubtful debts under Expected Credit Loss Model	(2.81)
Deferred tax on above adjustments	0.61
Net profit for the period as per Ind AS	35.90

(vi) The Shareholders vide a special resolution approved sub division of shares of the Company in the ratio of 5 shares of face value of ₹ 2 each for every existing 1 share of the face value of ₹ 10 each through postal ballot. The requisite approvals for modification of the Memorandum and Articles of Association of the Company had been accorded by the shareholders on 4 May 2017. Accordingly, the earnings per share for the previous period has been restated in accordance with Ind AS 33 "Earnings Per Share".

(vii) The Company operates only in one primary business segment viz. 'manufacturing and sales of enzymes'.

(viii) On 3 July 2017, the Company completed its acquisition of Advanced Enzymes (Malaysia) Sdn. Bhd. formerly known as Palm Techno Ventures Enzyme Sdn Bhd ("PTVE"), Malaysia by way of an investment of 200,000 Malaysian Ringgit (RM), equivalent to ₹ 3.14 Million, in 200,000 ordinary shares of RM 1.00 each of PTVE i.e. 80% of the paid-up share capital of PTVE.

(ix) On 11 July 2017, the Company has incorporated a wholly owned subsidiary; Advanced Enzymes Europe B.V. in Amsterdam, Netherlands registered with Chamber of Commerce having a paid up share capital of Euro 2 million, equivalent to ₹ 149.85 Million.

(x) On 15 August 2017, Advanced Enzyme Europe B.V. based in Amsterdam has completed the 100% acquisition of Evovx Technologies GmbH (Evovx), Germany, for a consideration of Euro 7.65 million, equivalent to ₹ 579.13 Million.

(xi) The Board of Directors have recommended a payment of final dividend for the financial year 2016-17 of ₹ 0.40/- per equity share of ₹ 2/- each subject to the approval of shareholders.

(xii) Previous period's figures have been regrouped / reclassified where necessary, to conform to the current period's classification.

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited


C.L. Rathi
Managing Director
DIN : 00385691

Place: Thane

Dated: 11 September 2017

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Standalone Limited Review Report

To the Board of Directors of Advanced Enzyme Technologies Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') for the quarter ended 30 June 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2016 including the reconciliation of profit under Indian Accounting Standards (Ind AS) of the corresponding quarter with profit reported under previous GAAP, as reported in these unaudited standalone financial results, have been approved by the Company's Board of Directors but have not been subjected to review.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 11 September 2017. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022

Sadashiv Shetty
Partner

Membership No: 048648

Mumbai
11 September 2017